MADEINNOVITALY

MADEINNOVITALY


Invest in Italian high tech

With the support of two Swiss Venture Capital experts and on request of the Turin Chamber of Commerce, the Italian Chamber of Commerce in Zurich has selected 4 Italian start-ups from Torino to launch them on the Swiss Venture Capital Market.

Please check their profiles and let us know if you are interested in a preliminary meeting to know more about them.

APTSOL


Aptsol
Core Business

Formulation and development of dosage forms (such as emulsions, nanonized powders, polymeric matrix systems) or productions intermediate. Starting from your formulation issue APTSOL develops solutions, be it in the pharmaceutical, cosmetic or nutraceutical field. APTSOL has developed an equipment, called GELOSOL, to obtain formulations of high added value, in particular using microencapsulation techniques based on ionotropic gelationExamples of use : vinegar gelled beads, beads containing essential oils or creams.


Target Markets

Potential clients are SMEs active in the fields of cosmetics, essential oils, oil pearls, vinegar pearls, medicinal plants, dietary supplement, pharma and biotech SMEs. The Italian market for industrial equipment similar to GELOSOL has a size of € 285 Mil (Istat 2017), the italian export in EU is € 1 B (Istat 2017) and in the world € 2 B.


Competitive Advantage

GELOSOL works on a larger scale than the lab competition and is able to carry out a continuous production. It’s easier to use than its competitors and less expensive.


Financials
  • Product/ Service Market Price: € 30.000 – 50.000;
  • Present Production Level: Zero;
  • Production level needed to reach break even: 9 Gelosol;
  • Requested Investment size for start-up: € 280.000.

Website

www.aptsol.it


More Info

Letizia Simoncioni: lsimoncioni@ccis.ch

MORECOGNITION®


MORECOGNITION®
Core Business

Production of Remo®, a system equipped with artificial intelligence to assist patients with reduced motor functions in their domestic rehabilitation activities. Remo® ‘s wearable sensor mesures both movement and muscular activity during the excercises without direct therapist’s control. The data collected through the sensor are instantly transferred to the Remo®’s mobile App. Logging onto Remo®’s platform the therapist is able to evaluate each patient’s activity and to verify its compliance with the rehabilitation program.


Target Markets

Remo is part of the digital health market, valued € 20.21 B in 2016, expected to grow at a CAGR of 6.0%. The phisical rehab market involves two main actors: rehab patients and health professionals. Both are seen as target customers. Phisiotherapists represent the potential clients of the B2B market: the aim of Remo® is not to replace them but to optimise their work. The B2C potential clients consist of rehab patiens. Morecognition® itends to enter Italy, Germany, the Uk, France, Spain, the Netherlands and the US, whose total phisioterapists’ number amounts to 664.000.


Competitive Advantage

The rehabilitation path starts in the hospital and should continue as required at home: domestic care plays an integrated role for effective results. The services in developed countries mainly consist of a hospitalization period. There’s a lack of professional solutions to help the actors involved to exploit effective new helath-care delivery models. Using Remo® both patients and caregivers will gain advantages : the patient will be included in a motivating rehab program, seeing the data derived from his/her activities, the use of Remo® will be less expensive than the domestic presence of the care-giver during every session. The care-giver will have at disposal all datas to better adapt the rehab path in a more effective way.


Financials
  • Product/ Service Market Price: € 300, mobile app included (B2C), free for B2B;
  • Present Production Level: TRL7 (Technology Readiness Level);
  • Production level needed to reach break even: 2.850 sensors sold (B2C) and 360 therapists enrolled;
  • Requested Investment size for start-up: € 300.000.

Website

www.morecognition.com


More Info

Letizia Simoncioni: lsimoncioni@ccis.ch

TRACES


TRACES
Core Business

The Production of a Safety Biopsy Container for a safe handling of formalin and the production of chemicals to oxidize formalin vapors, the aim is to reduce or avoid contact from operators of formalin vapors, during biopsy and Lab operations. The patented containers are prefilled with formalin in the upper part of the containers. After the closure of the container the formalin is released, avoiding any direct contact for the operators. The chemical product, called NOWOK, destroys by oxidation all formalin vapors.


Target Markets

Potential clients are distributors for Healthcare facilities, mainly focused on biopsy and laboratories.


Competitive Advantage

The guarantee of a safe handling of formalin.


Financials
  • Product/ Service Market Price: Biopsy Containers: from € 1.80 to € 25.00 - NOVOK: from € 12.00 to € 145.00;
  • Present Production Level: Biopsy Containers: 500.000 pcs/year - NOVOK : has started on September;
  • Production level needed to reach break even: Biopsy Containers:1.500.000 ;
  • Requested Investment size for start-up: For Biopsy Container & NOVOK : about € 1.500.00 – 2.000.000.

Website

www.novok.it


More Info

Letizia Simoncioni: lsimoncioni@ccis.ch

VIVACSO


VIVACSO
Core Business

The production of Ópponent®, an AFO (Ankle-foot orthosis) active for the first time ever on the frontal plane (on which the foot twists) rather than on the longitudinal plane.


Target Markets

The potential clients of Ópponent® AFOs (neurological and orthopedic) are all rehab departments and centres, all orthopedic workshops or drugstores with orthopaedic area, and patients themselves. Spasticity of the foot currently affects about 4.800.00 European citizens suffering from hemiparesis after stroke. Patients with spasticity from multiple sclerosis are roughly 500.000 in EU and patients with ankle sprain are over 17 million/year in EU.


Competitive Advantage

The first need of every patient with Ankle-foot problems is the gait autonomy. Exsisting commercial orthoses are poorely efficacious for gait improvement, functional surgery or botulinum toxic infiltrations are both poorly efficacious and invasive. Ópponent® provides an improved stability during the gait, supporting the foot weight when it drops, (like other AFOs) it abolishes for the first time the torsional movement of the forefoot on the frontal plane (like no other AFO). Moreover the aesthetic and handliness value of Ópponent® is far superior to competitors. The buyable online accessories (seasonal covers, customizations, laces in different shapes and textile) will be many, cool and Italian style.


Financials
  • Product/ Service Market Price: Customer price: € 370, retailer price: € 210;
  • Present Production Level: Ready to launch Ópponent® version for neurological patiens, orthopedic will follow;
  • Production level needed to reach break even: 3.000 pcs ;
  • Requested Investment size for start-up: € 300.000.

Website

www.vivacso.com


More Info

Letizia Simoncioni: lsimoncioni@ccis.ch